Botulinum toxin in the management of spasticity in adults
Lynne Turner-Stokes and Anthony Ward
DOI: https://doi.org/10.7861/clinmedicine.2-2-128
Clin Med March 2002 Lynne Turner-Stokes
Regional Rehabilitation Unit, Northwick Park Hospital, Middlesex
DM FRCPAnthony Ward
North Staffordshire Rehabilitation Centre, North Staffordshire Hospital, Stoke-on-Trent
FRCP FRCP EdinAbstract
Botulinum toxin (BTX) is a powerful neurotoxin which blocks cholinergic transmission at the neuromuscular junction. Judiciously applied, it can reduce local muscle overactivity while maintaining the strength in other muscles. To date BTX has not been licensed for use in spasticity in the UK and the literature pertaining to clinical practice is still relatively scant. However, controlled trials have provided evidence of the effectiveness of BTX both in reducing spasticity itself and in achieving functional gain. The guidance given here to clinicians involved in the management of spasticity covers the types of patient suitable for treatment using BTX, the appropriate dosage, and the necessary follow-up procedures and documentation.
- © 2002 Royal College of Physicians
Article Tools
Botulinum toxin A in the management of spasticity
Lynne Turner-Stokes, Anthony Ward
Clinical Medicine Mar 2002, 2 (2) 128-130; DOI: 10.7861/clinmedicine.2-2-128
Citation Manager Formats
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.